Yusuke Nakamura to Treatment Outcome
This is a "connection" page, showing publications Yusuke Nakamura has written about Treatment Outcome.
Connection Strength
0.851
-
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.
Score: 0.070
-
Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment. Hum Mol Genet. 2018 08 01; 27(15):2671-2677.
Score: 0.056
-
Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. Clin Cancer Res. 2017 04 15; 23(8):2019-2026.
Score: 0.050
-
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug; 49(2):471-8.
Score: 0.049
-
TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22; 6(259):259ra145.
Score: 0.043
-
Lobectomy of pulmonary metastasis of endometrial stromal sarcoma. Tokai J Exp Clin Med. 2013 Dec 20; 38(4):142-5.
Score: 0.041
-
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet. 2013 Jun; 58(6):327-33.
Score: 0.039
-
Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level. Jpn J Clin Oncol. 2011 Aug; 41(8):1023-30.
Score: 0.034
-
Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011 Feb; 11(2):185-93.
Score: 0.034
-
Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol. 2010 Jul; 40(7):684-9.
Score: 0.032
-
Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol. 2009 Feb; 34(2):361-70.
Score: 0.029
-
Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Front Immunol. 2025; 16:1571182.
Score: 0.022
-
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005 Apr 01; 11(7):2625-36.
Score: 0.022
-
Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004 Mar; 24(3):647-55.
Score: 0.021
-
Prediction of response to imatinib by cDNA microarray analysis. Semin Hematol. 2003 Apr; 40(2 Suppl 2):42-9.
Score: 0.020
-
Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia. 2002 Jul-Aug; 4(4):295-303.
Score: 0.019
-
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. J Immunol. 2018 10 01; 201(7):1967-1974.
Score: 0.014
-
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. J Immunother. 2018 May; 41(4):201-207.
Score: 0.014
-
Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. Cancer Sci. 2018 Mar; 109(3):600-610.
Score: 0.014
-
Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017 May; 50(5):1655-1662.
Score: 0.013
-
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res. 2017 02 28; 36(1):36.
Score: 0.013
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
Score: 0.013
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.012
-
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015 Jan 15; 21(2):312-21.
Score: 0.011
-
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med. 2014 Mar 10; 12:63.
Score: 0.010
-
Colorectal cancer metastasis to the thyroid. Osaka City Med J. 2012 Dec; 58(2):67-75.
Score: 0.010
-
Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C. J Gen Virol. 2013 Jan; 94(Pt 1):81-89.
Score: 0.009
-
Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology. 2012; 55(6):417-25.
Score: 0.009
-
Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol. 2012 Jul; 42(7):591-600.
Score: 0.009
-
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet. 2012 Apr 01; 21(7):1665-72.
Score: 0.009
-
Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012; 55(3):231-41.
Score: 0.009
-
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011 Jul 01; 204(1):84-93.
Score: 0.009
-
Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2011 Jun; 83(6):981-8.
Score: 0.009
-
Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011 Jun; 83(6):1048-57.
Score: 0.009
-
IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011 Jun; 54(6):1094-101.
Score: 0.008
-
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J Gen Virol. 2011 May; 92(Pt 5):1071-1081.
Score: 0.008
-
A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. J Hepatol. 2011 Apr; 54(4):629-39.
Score: 0.008
-
HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. 2011 Feb; 60(2):261-7.
Score: 0.008
-
Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol. 2011 Mar; 54(3):408-14.
Score: 0.008
-
ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010 Oct; 139(4):1190-7.
Score: 0.008
-
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009 Aug; 100(8):1502-9.
Score: 0.007
-
Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med. 2009 Jul; 23(5):479-85.
Score: 0.007
-
A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology. 2009 May; 136(5):1796-805.e6.
Score: 0.007
-
Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res. 2002 Aug; 93(8):849-56.
Score: 0.005